• NICE says no to expanding use of AZ’ Lynparza pharmatimes
    November 12, 2018
    The National Institute for Health and Care Excellence has ruled against expanding use of AstraZeneca’s Lynparza to a wider patient population with ovarian cancer.
PharmaSources Customer Service